Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus

Rheumatology (United Kingdom)

Volumn 53, Issue 8, 2014, Pages 1470-1476

  Ruiz Arruza, Ioana ^a   Ugarte, Amaia ^a   Cabezas Rodriguez, Ivan ^a   Medina, Jose Alejandro ^a   Moran, Miguel Angel ^a   Ruiz Irastorza, Guillermo ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Avascular osteonecrosis; Cataract; Diabetes mellitus; Glucocorticoids; Methylprednisolone; Osteoporosis; Prednisone; Systemic lupus erythematosus

Indexed keywords

METHYLPREDNISOLONE; PREDNISONE;

ADULT; ARTICLE; AVASCULAR NECROSIS; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL EVALUATION; COHORT ANALYSIS; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG INDUCED DISEASE; DRUG PULSE THERAPY; EYE DISEASE; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HUMAN; HYPOGONADISM; KIDNEY DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEOPLASM; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PSYCHOPATHY; SKIN DISEASE; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

AVASCULAR OSTEONECROSIS; CATARACT; DIABETES MELLITUS; GLUCOCORTICOIDS; METHYLPREDNISOLONE; OSTEOPOROSIS; PREDNISONE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; CATARACT; COHORT STUDIES; DIABETES MELLITUS; FEMALE; GLUCOCORTICOIDS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OSTEONECROSIS; OSTEOPOROTIC FRACTURES; PREDNISONE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84904872260     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu148     Document Type: Article

References (25)

1. Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther 2012;14(Suppl 4):S4.
2. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004;50:3408-17.
3. Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology 2012;51:1145-53.
4. Zonana-Nacach A, Barr SG, Magder LS, Petri MA. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-8.
5. Thamer M, Hernán MA, Zhang Y, Cotter D, Petri MA. Prednisone, lupus activity and permanent organ damage. J Rheumatol 2009;36:560-4.
6. Gladman DD, Urowitz MB, Rahman P, Ibanẽz D, Tam L-S. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955-9.
7. Fischer-Betz R, Chehab G, Sander O et al. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study. J Rheumatol 2012;39:2111-7.
8. Ruiz-Irastorza G, Espinosa G, Frutos MA et al. Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.). Nefrologia 2012;32:S1-35.
9. Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum 2003;32:370-377.
10. Gladman D, Ginzler E, Goldsmith C, Fortin P et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
11. Gladman DD, Urowitz MB, Goldsmith C. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13.
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
13. Gladman DD, Ibanẽz D, Urowitz MB. SLE Disease Activity Index 2000. J Rheumatol 2002;29:288-91.
14. Molad Y, Gorshtein A, Wysenbeek AJ et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 2002;11:356-61.
15. Alarcon GS, Roseman JM, McGwin G Jr et al. Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology 2004;43:202-5.
16. Fessler BJ, Alarcon GS, Mcgwin G et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473-80.
17. Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 2012;64:4021-8.
18. Chambers SA, Allen E, Rahman A, Isenberg DA. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology 2009;48:673-5.
19. Ruiz-Irastorza G, Egurbide M-V, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004;164:77-82.
20. Meacock R, Dale N, Harrison MJ. The humanistic and economic burden of systemic lupus erythematosus: a systematic review. Pharmacoeconomics 2013;31:49-61.
21. Nossent JC. SLICC/ACR damage index in Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy and prognosis. J Rheumatol 1998;25:654-9.
22. Bultink IEM, Lems WF, Kostene PJ, Dijkmans BAC, Voskuyl AE. Prevalence and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 2005;54:2044-50.
23. Kong KO, Badsha H, Lian TY, Edwards CJ, Chng HH. Low-dose pulse methylprednisolone is an effective therapy for severe SLE flares. Lupus 2004;13:212-3.
24. Ruiz-Irastorza G, Danza A, Perales I et al. Prednisone in lupus nephritis: how much is enough? Autoimmun Rev 2014;13:206-14.
25. Condon MB, Ashby D, Pepper RJ et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-6.